Baird Medical to Participate in COSM 2025 Conference

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, has announced its participation in the 2025 Combined Otolaryngology Spring Meetings (COSM) scheduled for May 14-18, 2025, in New Orleans, Louisiana.

COSM is a prestigious international gathering for the otolaryngology-head and neck surgery community, bringing together multiple leading societies. The conference provides Baird Medical with a strategic platform to showcase its MWA technology portfolio and engage with key opinion leaders, clinicians, researchers, and potential strategic partners in the otolaryngology field.

NEW YORK, May 5, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, is pleased to announce its participation in the 2025 Combined Otolaryngology Spring Meetings (COSM), taking place May 14-18, 2025, in New Orleans, Louisiana.

COSM is internationally recognized as one of the foremost meetings globally for the otolaryngology-head and neck surgery community. By convening multiple leading otolaryngology societies, the conference serves as a comprehensive academic platform dedicated to disseminating cutting-edge research, delivering advanced clinical education, and fostering collaboration among specialists to enhance patient care in head and neck medicine and surgery.

Baird Medical's participation in COSM highlights the expanding applications and growing interest of its advanced MWA technology within the diverse field of otolaryngology. This prestigious event offers a strategic opportunity for the Company to engage with key opinion leaders, leading clinicians, researchers, and potential strategic partners all over the world, while showcasing its portfolio of innovative, minimally invasive solutions.

Baird Medical remains dedicated to advancing minimally invasive treatments and looks forward to collaborating with healthcare professionals at COSM to explore groundbreaking approaches and integrated care strategies that can enhance patient outcomes across various otolaryngological applications.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-to-participate-in-cosm-2025-conference-302445655.html

SOURCE BDMD

FAQ

When and where is Baird Medical (BDMD) participating in COSM 2025?

Baird Medical will participate in COSM 2025 from May 14-18, 2025, in New Orleans, Louisiana.

What is Baird Medical's (BDMD) main technology focus?

Baird Medical specializes in minimally invasive Microwave Ablation (MWA) technology.

What is the significance of COSM 2025 for Baird Medical (BDMD)?

COSM is a major international conference that allows Baird Medical to showcase its MWA technology, engage with key opinion leaders, and explore potential partnerships in the otolaryngology field.

What is the purpose of Baird Medical's (BDMD) participation in COSM 2025?

The company aims to showcase its portfolio of minimally invasive solutions, engage with healthcare professionals, and explore new approaches to enhance patient outcomes in otolaryngological applications.